NCT06068621CompletedPhase 2
Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia
Multicenter,Open Label,Phase 2 Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Source: ClinicalTrials.gov · Last updated 20 Jan 2026
Brief summary (registry, in English)
The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed acute myeloid leukemia.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (actual)
- First submitted
- 29 Sept 2023
- Start date
- 1 Mar 2023
- Primary completion date
- 31 May 2024
- Lead sponsor
- Chinese PLA General Hospital
- Diseases
- Acute myeloid leukemia, Childhood cancers
- NCT number
- NCT06068621
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 200
- From 1 Mar 2023 to the primary completion date, 31 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Less than 6 weeks after surgical operation of important organs.
Other illness
- Patients with allergy or contraindication to the study drug;
- Patients with a known history of alcohol or drug addiction on the basis that there could be a higher risk of non-compliance to study treatment;
- Patients with mental illness or other states unable to comply with the protocol;
Lab values
- Liver function: ALT and AST\>2.5 times the upper limit of normal ,bilirubin\> 2 times the upper limit of normal;Renal function: creatinine \>the upper limit of normal;
Other
- Female patients who are pregnant or breast-feeding.
- The patient is not suitable for this clinical trial (poor compliance, substance abuse, etc.)
Who the study is looking for
- Patients who are able to understand and willing to sign the informed consent form (ICF).
- All patients should aged 14 to75 years,no gender limitation.
- Patients who are newly diagnosed with AML(no M3).
- Liver function: ALT and AST≤2.5 times the upper limit of normal ,bilirubin≤2 times the upper limit of normal;
- Renal function: creatinine ≤the upper limit of normal;
- Patients without any uncontrolled infections , without organ dysfunction or without severe mental illness;
- The score of Eastern Cooperative Oncology Group (ECOG) is 0-2, and the predicted survival ≥ 4 months.
- Patients without severe allergic constitution.
Age in the registry: 14 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese PLA General Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.